{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-041838","form_type":"8-K","ticker":"RANI","cik":"0001856725","company_name":"Rani Therapeutics Holdings, Inc.","filed_at":"2023-08-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:35.826407+00:00","generated_at":"2026-06-11T15:30:44.101531+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Rani Therapeutics Q2 2023 net loss $18.7M; cash $74.6M; expands Celltrion partnership","bullets":["Net loss of $18.7M for Q2 2023, up from $16.0M in Q2 2022; cash and securities $74.6M (down from $98.5M at YE 2022).","Expanded Celltrion partnership to develop RT-105 (adalimumab biosimilar) using high-capacity RaniPill HC device.","Appointed Kate McKinley as Chief Business Officer, bringing 20 years of biopharma experience.","Plan to initiate Phase 2 for RT-102 and Phase 1 for RT-111 (monoclonal antibody) in H2 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-041838","json":"https://secwatch.observer/filing/0000950170-23-041838.json","markdown":"https://secwatch.observer/filing/0000950170-23-041838.md","text":"https://secwatch.observer/filing/0000950170-23-041838.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1856725/000095017023041838/0000950170-23-041838-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1856725/000095017023041838/rani-20230811.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T15:30:44.101531+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"ea3191f4c008f3887992dd7e0f3003093e920ce6","claim":"Rani Therapeutics Holdings, Inc. reported second quarter ended June 30, 2023 results: net income Net loss for the three months ended June 30, 2023, was $18.7 million.","evidence_excerpt":"On August 11, 2023, Rani Therapeutics Holdings, Inc. (the “Company”) issued a press release providing a corporate update and announcing its financial results for the second quarter ended June 30, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1856725/000095017023041838/0000950170-23-041838-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"second quarter ended June 30, 2023"},{"label":"Net income","value":"Net loss for the three months ended June 30, 2023, was $18.7 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}